Inogen (NASDAQ:INGN) Raised to Buy at StockNews.com

StockNews.com upgraded shares of Inogen (NASDAQ:INGN) from a hold rating to a buy rating in a research report released on Tuesday morning.

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a research note on Friday, November 8th.

Inogen Stock Up 1.0 %

Shares of INGN opened at $10.05 on Tuesday. The company has a market capitalization of $239.39 million, a price-to-earnings ratio of -4.47 and a beta of 1.04. Inogen has a 52 week low of $4.93 and a 52 week high of $13.33. The stock’s 50-day moving average price is $9.82 and its 200-day moving average price is $9.52.

Institutional Trading of Inogen

A number of hedge funds and other institutional investors have recently made changes to their positions in INGN. Meeder Asset Management Inc. acquired a new position in shares of Inogen in the 2nd quarter worth approximately $30,000. Quarry LP acquired a new stake in Inogen during the 3rd quarter worth about $59,000. CWM LLC lifted its position in shares of Inogen by 2,185.9% in the 2nd quarter. CWM LLC now owns 6,629 shares of the medical technology company’s stock valued at $54,000 after acquiring an additional 6,339 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Inogen in the first quarter valued at $81,000. Finally, Pitcairn Co. acquired a new stake in shares of Inogen in the first quarter worth $86,000. 89.94% of the stock is currently owned by institutional investors.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.